<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02165826</url>
  </required_header>
  <id_info>
    <org_study_id>RO-2455-302-RD</org_study_id>
    <secondary_id>U1111-1150-2477</secondary_id>
    <secondary_id>2013-001788-21</secondary_id>
    <nct_id>NCT02165826</nct_id>
  </id_info>
  <brief_title>Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD</brief_title>
  <acronym>OPTIMIZE</acronym>
  <official_title>A Multicenter, Randomized, Double-blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-titration Regimen in COPD, Including an Open-label Down-titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg Roflumilast Once Daily in Subjects Not Tolerating 500 μg Roflumilast Once-daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate discontinuation rates of roflumilast using an
      up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of
      500 μg one daily (OD) during the entire 12-week main period, and to evaluate if participants
      who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD
      similar to that observed in other participants with the 500 μg OD dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Roflumilast is a product which has been approved for the treatment of severe chronic
      obstructive lung disease (COPD) and its approved dose is 500μg once daily. This study is
      primarily designed to see whether alternation in this dose can improve tolerability of
      Roflumilast in COPD patients. Therefore one in three patients will start roflumilast therapy
      at a lower dose of 250μg once daily, another one in three will only take the 500μg tablet
      every other day (and one placebo every other day). Rest of them will start the regular dose
      of 500μg once daily right away and see whether starting with a lower dose of Roflumilast will
      lead to better tolerability. Furthermore, the study will see if patients who do not tolerate
      roflumilast should be given a lower dose of 250μg once daily.

      Lastly, the study will investigate what the body does to roflumilast. Patients with a history
      of COPD for at least last 12 months and a former smoker or current smoker with history of at
      least 10 pack years will be invited to participate.

      The main study period lasts for a maximum of 15 weeks and patients will have to visit the
      study site up to 6 times. If patients are not tolerating roflumilast, the investigators may
      switch them to the down titration period where they may be on a lower dose for rest of the
      study. Then patients will remain in the down titration period for additional 8 weeks and will
      have to visit the study site 4 times. Most of the visits will take approximately 1 to 2
      hours. However, one visit in the main period and 1 or 2 visits in the down titration period
      will take approximately 6 to 7 hours. These visits are longer to allow time to conduct blood
      taking.

      The Randomization visit is considered the Baseline visit and for participants that
      discontinue the Main Period and continue into the Down-Titration Period Day 1 of Down
      Titration is considered BaselineDT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2014</start_date>
  <completion_date type="Actual">September 1, 2015</completion_date>
  <primary_completion_date type="Actual">September 1, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason</measure>
    <time_frame>Baseline to Week 12 (Main Period)</time_frame>
    <description>The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events of Interest</measure>
    <time_frame>Baseline to Week 12 (Main Period)</time_frame>
    <description>Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period</measure>
    <time_frame>Baseline (V0DT) [assessment at end of main period] and Final Visit of Down-Titration Period (Up to Day 56)</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period</measure>
    <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Week 8 (Down-Titration Period)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period</measure>
    <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period</measure>
    <time_frame>Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)</time_frame>
    <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period</measure>
    <time_frame>Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)</time_frame>
    <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period</measure>
    <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)</time_frame>
    <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Treatment Satisfaction Scores During the Main Period</measure>
    <time_frame>Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)</time_frame>
    <description>Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period</measure>
    <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)</time_frame>
    <description>Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
    <description>PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
    <description>PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
    <description>PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
    <description>PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total PDE4 Inhibitory Activity (tPDE4i)</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.</time_frame>
    <description>tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.</time_frame>
    <description>tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Simulated Percentage of Participants With Adverse Events of Interest</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. AEIs: 12 Weeks</time_frame>
    <description>The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates [weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12</measure>
    <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. FEV-1: Pre-dose and Weeks 4 and 12</time_frame>
    <description>The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates [weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1323</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Roflumilast 500 μg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast 500 μg every other day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roflumilast 250 μg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Roflumilast tablets</description>
    <arm_group_label>Roflumilast 500 μg once daily</arm_group_label>
    <arm_group_label>Roflumilast 500 μg every other day</arm_group_label>
    <arm_group_label>Roflumilast 250 μg once daily</arm_group_label>
    <other_name>Daxas, Daliresp, Libertek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast Placebo</intervention_name>
    <description>Roflumilast placebo-matching tablets</description>
    <arm_group_label>Roflumilast 500 μg every other day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care COPD Treatment</intervention_name>
    <description>The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.</description>
    <arm_group_label>Roflumilast 500 μg once daily</arm_group_label>
    <arm_group_label>Roflumilast 500 μg every other day</arm_group_label>
    <arm_group_label>Roflumilast 250 μg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In the opinion of the investigator, the participant is capable of understanding and
             complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Has a history of chronic obstructive pulmonary disease (COPD) (according to Global
             Initiative for Chronic Obstructive Lung Disease (GOLD) 2013) for at least 12 months
             prior to Screening (Visit V0) associated with chronic productive cough for 3 months in
             each of the 2 years prior to Screening (Visit V0, with other causes of productive
             cough excluded).

          4. Shows a post-bronchodilator forced expiratory volume in 1 second (FEV1) of ≤50% of
             predicted.

          5. Shows an FEV1/forced vital capacity (FVC) ratio (post-bronchodilator) &lt;70%.

          6. Has at least one documented COPD exacerbation within one year prior to Screening
             (Visit V0).

          7. Is on standard of care COPD maintenance treatment including Long Acting β2-Agonist
             (LABAs), long-acting anticholinergics, or any combination thereof taken on a constant
             daily dose within 12 weeks prior to Screening (Visit V0).

          8. Must be a former smoker (defined as smoking cessation at least one year ago) or
             current smoker both with a smoking history of at least 10 pack years.11

          9. Is male or female and aged 40 or older.

         10. A female participant of childbearing potential who is sexually active with a
             nonsterilized male partner agrees to use routinely adequate contraception from signing
             of informed consent throughout the duration of the study.

        Exclusion Criteria:

        Criteria affecting the read-out parameters of the study

          1. Has a COPD exacerbation ongoing at the Screening (Visit V0), or has a COPD
             exacerbation between V0 and V1.

          2. Has a lower respiratory tract infection not resolved 4 weeks prior to Screening (Visit
             V0).

          3. Has a diagnosis of asthma and/or other relevant lung disease (eg, history of primary
             bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer,
             interstitial lung disease [eg, fibrosis, silicosis, sarcoidosis], or active
             tuberculosis).

          4. Has a known α1-antitrypsin deficiency.

          5. Has taken roflumilast within 6 months of Screening (Visit V0).

             Criteria within ethical considerations in terms of general health

          6. Has clinically relevant abnormal laboratory values suggesting an undiagnosed disease
             requiring further clinical evaluation (as assessed by the investigator).

          7. Has a history of severe psychiatric or neurological disorders.

          8. Has a history of depression associated with suicidal ideation or behavior.

          9. Has congestive heart failure severity grade IV according to New York Heart Association
             (NYHA) Functional Classification.

         10. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.

         11. Has computed tomography (CT) or chest x-ray findings indicating an acute pulmonary
             disease other than COPD (eg, tuberculosis, severe bronchiectasis, tumors).

         12. Has severe immunological diseases (eg, known human immune deficiency virus (HIV)
             infection, multiple sclerosis, lupus erythematosus, progressive multifocal
             leukoencephalopathy).

         13. Has liver impairment Child-Pugh B or C and/or active viral hepatitis.

         14. Has severe acute infectious diseases (eg, tuberculosis, or acute hepatitis).

         15. Has a history of malignant disease (except basal cell carcinoma) within 5 years before
             Screening (Visit V0).

         16. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within one year before Screening (Visit V0).

         17. Has a history of hypersensitivity or allergies to roflumilast or rescue medication or
             ingredients thereof, or any other contraindication for the use thereof.

         18. If female, the participant is pregnant or lactating or intending to become pregnant
             before, during, or within 12 weeks after participating in this study; or intending to
             donate ova during such time period.

         19. Intends to donate blood, organs, or bone marrow during the course of the study.

         20. Has received any investigational compound within 30 days prior to Screening (Visit
             V0), is currently participating in another interventional clinical study, or has been
             previously enrolled in this study.

         21. Is suspected to be unable or unwilling to comply with study procedures (eg, language
             problems, psychological disorders, number and timing of visits at the center).

         22. Suffers from any concomitant disease that might interfere with study procedures or
             evaluations.

         23. Is required to take excluded medications.

         24. Is an immediate family member, study center employee, or is in a dependent
             relationship with a study site employee who is involved in conduct of this study (eg,
             spouse, parent, child, sibling), or may consent under duress.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <results_first_submitted>September 16, 2016</results_first_submitted>
  <results_first_submitted_qc>January 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 14, 2017</results_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 161 investigative sites in Bulgaria, Germany, Greece, Hungary, Korea, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Spain, Thailand, Ukraine and the United Kingdom from 30 April 2014 to 21 October 2015.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) were enrolled equally in 1 of 3 treatment groups in the Main Treatment Period: roflumilast 250 μg then 500 μg once daily (OD), 500 μg every other day (EOD) then 500 μg OD and 500 μg OD. Participants who discontinued received 250 μg in the Down-Titration Period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Roflumilast 250 μg OD Then 500 μg OD</title>
          <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="P2">
          <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
          <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="P3">
          <title>Roflumilast 500 μg OD</title>
          <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="439"/>
                <participants group_id="P3" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set: Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="437"/>
                <participants group_id="P3" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="349"/>
                <participants group_id="P3" count="334"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="109"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pre-treatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major/Significant Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Down-Titration Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set: Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pre-treatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set (SAS) included all randomized participants who took at least one dose of study medication. Main Treatment Period.</population>
      <group_list>
        <group group_id="B1">
          <title>Roflumilast 250 μg OD Then 500 μg OD</title>
          <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="B2">
          <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
          <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="B3">
          <title>Roflumilast 500 μg OD</title>
          <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="441"/>
            <count group_id="B2" value="437"/>
            <count group_id="B3" value="443"/>
            <count group_id="B4" value="1321"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="7.81"/>
                    <measurement group_id="B2" value="65.0" spread="8.21"/>
                    <measurement group_id="B3" value="64.6" spread="8.36"/>
                    <measurement group_id="B4" value="64.6" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>40-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="224"/>
                    <measurement group_id="B4" value="668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="217"/>
                    <measurement group_id="B4" value="651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years and over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="325"/>
                    <measurement group_id="B3" value="338"/>
                    <measurement group_id="B4" value="983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="423"/>
                    <measurement group_id="B3" value="426"/>
                    <measurement group_id="B4" value="1277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="399"/>
                    <measurement group_id="B3" value="405"/>
                    <measurement group_id="B4" value="1209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic Of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.1" spread="8.73"/>
                    <measurement group_id="B2" value="168.8" spread="8.66"/>
                    <measurement group_id="B3" value="169.1" spread="8.55"/>
                    <measurement group_id="B4" value="169.0" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.59" spread="18.627"/>
                    <measurement group_id="B2" value="74.31" spread="17.808"/>
                    <measurement group_id="B3" value="75.68" spread="16.949"/>
                    <measurement group_id="B4" value="75.20" spread="17.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.36" spread="5.957"/>
                    <measurement group_id="B2" value="25.98" spread="5.614"/>
                    <measurement group_id="B3" value="26.44" spread="5.888"/>
                    <measurement group_id="B4" value="26.26" spread="5.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="247"/>
                    <measurement group_id="B4" value="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Cigarette Pack-Years</title>
          <description>Number of pack-years = (number of cigarettes smoked per day/20) × number of years smoked</description>
          <units>pack-years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.1" spread="17.49"/>
                    <measurement group_id="B2" value="40.2" spread="19.22"/>
                    <measurement group_id="B3" value="37.6" spread="17.70"/>
                    <measurement group_id="B4" value="38.6" spread="18.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in the First Second (FEV1)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.022" spread="0.3177"/>
                    <measurement group_id="B2" value="1.028" spread="0.3173"/>
                    <measurement group_id="B3" value="1.018" spread="0.3289"/>
                    <measurement group_id="B4" value="1.023" spread="0.3211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-Bronchodilator Forced Vital Capacity (FVC)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.304" spread="0.7418"/>
                    <measurement group_id="B2" value="2.303" spread="0.7091"/>
                    <measurement group_id="B3" value="2.314" spread="0.6822"/>
                    <measurement group_id="B4" value="2.307" spread="0.7109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason</title>
        <description>The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.</description>
        <time_frame>Baseline to Week 12 (Main Period)</time_frame>
        <population>Safety Analysis Set (SAS) included all randomized participants who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD</title>
            <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason</title>
          <description>The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.</description>
          <population>Safety Analysis Set (SAS) included all randomized participants who took at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="20.1"/>
                    <measurement group_id="O3" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses were performed using a hierarchical testing procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses were performed using a hierarchical testing procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with study treatment and country as class effects, and baseline FEV1 as a continuous variable.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses were performed using a hierarchical testing procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.114</p_value>
            <p_value_desc>Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses were performed using a hierarchical testing procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Cox proportional hazards model with study treatment and country as class effects, and baseline FEV1 as a continuous variable.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events of Interest</title>
        <description>Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.</description>
        <time_frame>Baseline to Week 12 (Main Period)</time_frame>
        <population>SAS included all randomized participants who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD</title>
            <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events of Interest</title>
          <description>Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.</description>
          <population>SAS included all randomized participants who took at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4"/>
                    <measurement group_id="O2" value="48.3"/>
                    <measurement group_id="O3" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses were performed using a hierarchical testing procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.47</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses were performed using a hierarchical testing procedure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <p_value_desc>Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline (V0DT) [assessment at end of main period] and Final Visit of Down-Titration Period (Up to Day 56)</time_frame>
        <population>Participants from the Down-Titration Period Full Analysis Set (FAS), all randomized participants who entered this period, regardless of whether they took study medication, with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 250 μg once daily (OD) then 500 μg OD who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD_Down-Titration Period</title>
            <description>Participants in the roflumilast 500 μg, every other day (EOD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 500 μg once daily (OD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.</description>
          <population>Participants from the Down-Titration Period Full Analysis Set (FAS), all randomized participants who entered this period, regardless of whether they took study medication, with data available for analysis.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.030" spread="0.2294"/>
                    <measurement group_id="O2" value="0.055" spread="0.4170"/>
                    <measurement group_id="O3" value="0.007" spread="0.3555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period</title>
        <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Week 8 (Down-Titration Period)</time_frame>
        <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 250 μg once daily (OD) then 500 μg OD who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD_Down-Titration Period</title>
            <description>Participants in the roflumilast 500 μg, every other day (EOD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 500 μg once daily (OD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period</title>
          <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)</time_frame>
        <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication. &quot;n&quot; in each category is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 250 μg once daily (OD) then 500 μg OD who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD_Down-Titration Period</title>
            <description>Participants in the roflumilast 500 μg, every other day (EOD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 500 μg once daily (OD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
          <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication. &quot;n&quot; in each category is the number of participants with data available at the given time-point.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (n=20, 32, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.128" spread="0.3708"/>
                    <measurement group_id="O2" value="0.223" spread="0.4101"/>
                    <measurement group_id="O3" value="0.097" spread="0.2532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=20, 29, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.162" spread="0.4274"/>
                    <measurement group_id="O2" value="0.218" spread="0.4443"/>
                    <measurement group_id="O3" value="0.070" spread="0.2067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=26, 39, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.162" spread="0.3311"/>
                    <measurement group_id="O2" value="0.261" spread="0.4616"/>
                    <measurement group_id="O3" value="0.127" spread="0.3334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period</title>
        <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)</time_frame>
        <population>Main Period FAS included all randomized participants, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD</title>
            <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period</title>
          <description>FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
          <population>Main Period FAS included all randomized participants, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=409, 406, 386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.067" spread="0.2299"/>
                    <measurement group_id="O2" value="0.094" spread="0.2573"/>
                    <measurement group_id="O3" value="0.094" spread="0.2566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=402, 389, 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.2605"/>
                    <measurement group_id="O2" value="0.115" spread="0.2629"/>
                    <measurement group_id="O3" value="0.116" spread="0.2440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=376, 367, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.104" spread="0.2659"/>
                    <measurement group_id="O2" value="0.161" spread="0.2765"/>
                    <measurement group_id="O3" value="0.133" spread="0.2705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=402, 411, 409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.117" spread="0.2690"/>
                    <measurement group_id="O2" value="0.141" spread="0.2882"/>
                    <measurement group_id="O3" value="0.122" spread="0.2705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period</title>
        <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)</time_frame>
        <population>Main Period FAS included all randomized participants, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD</title>
            <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period</title>
          <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
          <population>Main Period FAS included all randomized participants, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=409, 406, 386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.096" spread="0.4053"/>
                    <measurement group_id="O2" value="0.112" spread="0.4168"/>
                    <measurement group_id="O3" value="0.104" spread="0.4166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=402, 389, 365)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.139" spread="0.3826"/>
                    <measurement group_id="O2" value="0.143" spread="0.4172"/>
                    <measurement group_id="O3" value="0.149" spread="0.4173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=376, 367, 352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.4346"/>
                    <measurement group_id="O2" value="0.194" spread="0.4974"/>
                    <measurement group_id="O3" value="0.162" spread="0.4341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=402, 411, 409)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157" spread="0.4746"/>
                    <measurement group_id="O2" value="0.207" spread="0.4925"/>
                    <measurement group_id="O3" value="0.147" spread="0.4555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period</title>
        <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)</time_frame>
        <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 250 μg once daily (OD) then 500 μg OD who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD_Down-Titration Period</title>
            <description>Participants in the roflumilast 500 μg, every other day (EOD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 500 μg once daily (OD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period</title>
          <description>Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
          <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (n=20, 32, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.087" spread="0.5392"/>
                    <measurement group_id="O2" value="0.303" spread="0.5103"/>
                    <measurement group_id="O3" value="0.104" spread="0.4568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=20, 29, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.125" spread="0.6151"/>
                    <measurement group_id="O2" value="0.191" spread="0.4780"/>
                    <measurement group_id="O3" value="0.067" spread="0.3522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=26, 39, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.167" spread="0.5492"/>
                    <measurement group_id="O2" value="0.113" spread="0.5100"/>
                    <measurement group_id="O3" value="0.029" spread="0.4628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Treatment Satisfaction Scores During the Main Period</title>
        <description>Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)</time_frame>
        <population>Main Period FAS included all randomized participants, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD</title>
            <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD Then 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Treatment Satisfaction Scores During the Main Period</title>
          <description>Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.</description>
          <population>Main Period FAS included all randomized participants, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="441"/>
                <count group_id="O2" value="439"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15 (n=410, 408, 386)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.12"/>
                    <measurement group_id="O2" value="-0.3" spread="1.15"/>
                    <measurement group_id="O3" value="-0.3" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (n=403, 390, 366)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.23"/>
                    <measurement group_id="O2" value="-0.5" spread="1.16"/>
                    <measurement group_id="O3" value="-0.5" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57 (n=375, 369, 351)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.24"/>
                    <measurement group_id="O2" value="-0.6" spread="1.26"/>
                    <measurement group_id="O3" value="-0.5" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (n=407, 416, 412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.43"/>
                    <measurement group_id="O2" value="-0.5" spread="1.51"/>
                    <measurement group_id="O3" value="-0.3" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period</title>
        <description>Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.</description>
        <time_frame>Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)</time_frame>
        <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 250 μg once daily (OD) then 500 μg OD who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD_Down-Titration Period</title>
            <description>Participants in the roflumilast 500 μg, every other day (EOD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD_Down Titration Period</title>
            <description>Participants in the roflumilast 500 μg once daily (OD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period</title>
          <description>Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.</description>
          <population>Down-Titration Period Full Analysis Set (FAS) included all randomized participants who entered this period, regardless of whether they took study medication. &quot;n&quot; in each of the categories is the number of participants with data available at the given time-point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 (n=20, 32, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.85"/>
                    <measurement group_id="O2" value="-0.8" spread="1.57"/>
                    <measurement group_id="O3" value="-0.8" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (n=20, 29, 31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.01"/>
                    <measurement group_id="O2" value="-0.8" spread="1.75"/>
                    <measurement group_id="O3" value="-0.9" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (n=26, 39, 38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.23"/>
                    <measurement group_id="O2" value="-0.3" spread="2.15"/>
                    <measurement group_id="O3" value="-0.4" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide</title>
        <description>PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>All PK Participants_Roflumilast</title>
            <description>All PK participants who received any dose of roflumilast. Results for roflumilast.</description>
          </group>
          <group group_id="O2">
            <title>All PK Participants_Roflumilast N-oxide</title>
            <description>All PK participants who received any dose of rofumilast. Results for roflumilast N-oxide.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide</title>
          <description>PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
          <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
          <units>units per hour (1/h)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight=33.5 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=70 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=160 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90"/>
                    <measurement group_id="O2" value="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide</title>
        <description>PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>All PK Participants_Roflumilast</title>
            <description>All PK participants who received any dose of roflumilast. Results for roflumilast.</description>
          </group>
          <group group_id="O2">
            <title>All PK Participants_Roflumilast N-oxide</title>
            <description>All PK participants who received any dose of rofumilast. Results for roflumilast N-oxide.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide</title>
          <description>PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
          <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
          <units>liters per hour (L/h)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight=33.5 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=70 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=160 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23"/>
                    <measurement group_id="O2" value="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35"/>
                    <measurement group_id="O2" value="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50"/>
                    <measurement group_id="O2" value="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.64"/>
                    <measurement group_id="O2" value="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide</title>
        <description>PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>All PK Participants_Roflumilast</title>
            <description>All PK participants who received any dose of roflumilast. Results for roflumilast.</description>
          </group>
          <group group_id="O2">
            <title>All PK Participants_Roflumilast N-oxide</title>
            <description>All PK participants who received any dose of rofumilast. Results for roflumilast N-oxide.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide</title>
          <description>PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
          <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
          <units>liters (L)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight=33.5 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.0"/>
                    <measurement group_id="O2" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=70 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=160 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.2"/>
                    <measurement group_id="O2" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide</title>
        <description>PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
        <group_list>
          <group group_id="O1">
            <title>All PK Participants_Roflumilast</title>
            <description>All PK participants who received any dose of roflumilast. Results for roflumilast.</description>
          </group>
          <group group_id="O2">
            <title>All PK Participants_Roflumilast N-oxide</title>
            <description>All PK participants who received any dose of rofumilast. Results for roflumilast N-oxide.</description>
          </group>
        </group_list>
        <measure>
          <title>Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide</title>
          <description>PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.</description>
          <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration.</population>
          <units>L</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1238"/>
                <count group_id="O2" value="1238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight=33.5 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=70 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=160 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="468.8"/>
                    <measurement group_id="O2" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=92</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=former</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smoking=current</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sex=male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total PDE4 Inhibitory Activity (tPDE4i)</title>
        <description>tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.</time_frame>
        <population>Participants from the PK Set, all participants who had at least 1 quantifiable PK concentration, with data available. Study design only includes the 250 µg arm for analyses of this outcome measure in the Down-Titration period. Measured values are predicted values reported as median and 90% prediction interval.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD</title>
            <description>Roflumilast 500 μg, tablets, orally, every other day (EOD) in the Main Period.</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 250 μg OD</title>
            <description>Roflumilast 250 μg tablets, orally, once daily in the Main Period.</description>
          </group>
          <group group_id="O4">
            <title>Roflumilast 250 µg Down-Titration</title>
            <description>250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Total PDE4 Inhibitory Activity (tPDE4i)</title>
          <description>tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.</description>
          <population>Participants from the PK Set, all participants who had at least 1 quantifiable PK concentration, with data available. Study design only includes the 250 µg arm for analyses of this outcome measure in the Down-Titration period. Measured values are predicted values reported as median and 90% prediction interval.</population>
          <units>unitless</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="399"/>
                <count group_id="O3" value="404"/>
                <count group_id="O4" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.366" upper_limit="2.05"/>
                    <measurement group_id="O2" value="0.608" lower_limit="0.227" upper_limit="1.03"/>
                    <measurement group_id="O3" value="0.563" lower_limit="0.157" upper_limit="1.01"/>
                    <measurement group_id="O4" value="0.583" lower_limit="0.210" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age &lt; 65 (n=198,187,229,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.323" upper_limit="1.85"/>
                    <measurement group_id="O2" value="0.559" lower_limit="0.237" upper_limit="0.998"/>
                    <measurement group_id="O3" value="0.518" lower_limit="0.160" upper_limit="0.958"/>
                    <measurement group_id="O4" value="0.511" lower_limit="0.205" upper_limit="0.984"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age ≥ 65 to &lt; 75 (n=146,159,136,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="0.550" upper_limit="2.08"/>
                    <measurement group_id="O2" value="0.660" lower_limit="0.177" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.614" lower_limit="0.138" upper_limit="1.10"/>
                    <measurement group_id="O4" value="0.683" lower_limit="0.207" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age ≥ 75 (n=48,53,39,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" lower_limit="0.318" upper_limit="2.31"/>
                    <measurement group_id="O2" value="0.676" lower_limit="0.188" upper_limit="1.12"/>
                    <measurement group_id="O3" value="0.616" lower_limit="0.195" upper_limit="1.01"/>
                    <measurement group_id="O4" value="0.712" lower_limit="0.300" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight &lt; 60 kg (n=56,78,73,17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="0.591" upper_limit="2.64"/>
                    <measurement group_id="O2" value="0.755" lower_limit="0.258" upper_limit="1.22"/>
                    <measurement group_id="O3" value="0.653" lower_limit="0.156" upper_limit="1.12"/>
                    <measurement group_id="O4" value="0.934" lower_limit="0.325" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight ≥ 60 kg (n=336,321,331,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.339" upper_limit="1.99"/>
                    <measurement group_id="O2" value="0.592" lower_limit="0.223" upper_limit="1.01"/>
                    <measurement group_id="O3" value="0.552" lower_limit="0.158" upper_limit="0.971"/>
                    <measurement group_id="O4" value="0.538" lower_limit="0.202" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males (n=300,297,290,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.363" upper_limit="1.96"/>
                    <measurement group_id="O2" value="0.585" lower_limit="0.226" upper_limit="0.994"/>
                    <measurement group_id="O3" value="0.558" lower_limit="0.145" upper_limit="0.998"/>
                    <measurement group_id="O4" value="0.575" lower_limit="0.213" upper_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Females (n=92,102,114,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" lower_limit="0.468" upper_limit="2.38"/>
                    <measurement group_id="O2" value="0.696" lower_limit="0.260" upper_limit="1.15"/>
                    <measurement group_id="O3" value="0.618" lower_limit="0.189" upper_limit="1.01"/>
                    <measurement group_id="O4" value="0.626" lower_limit="0.217" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker (n=179,183,200,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.327" upper_limit="1.88"/>
                    <measurement group_id="O2" value="0.568" lower_limit="0.247" upper_limit="0.976"/>
                    <measurement group_id="O3" value="0.514" lower_limit="0.101" upper_limit="0.949"/>
                    <measurement group_id="O4" value="0.554" lower_limit="0.228" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former Smoker (n=213,216,204,56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.416" upper_limit="2.15"/>
                    <measurement group_id="O2" value="0.632" lower_limit="0.186" upper_limit="1.09"/>
                    <measurement group_id="O3" value="0.626" lower_limit="0.196" upper_limit="1.10"/>
                    <measurement group_id="O4" value="0.624" lower_limit="0.207" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)</title>
        <description>tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.</time_frame>
        <population>PK Set included all participants who had at least 1 quantifiable PK concentration. &quot;n&quot; in the category is the number of participants with available data. Study design only includes the 250 µg OD and 500 µg OD arms for analyses of this outcome measure. Measured values are predicted values reported as median and 90% prediction interval.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 250 μg OD</title>
            <description>Roflumilast 500 μg at least one dose in the Main Period followed by Roflumilast 250 μg tablets, orally, once daily in the Down -Titration Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)</title>
          <description>tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.</description>
          <population>PK Set included all participants who had at least 1 quantifiable PK concentration. &quot;n&quot; in the category is the number of participants with available data. Study design only includes the 250 µg OD and 500 µg OD arms for analyses of this outcome measure. Measured values are predicted values reported as median and 90% prediction interval.</population>
          <units>unitless</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1114"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Participants (n=1114,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="0.352" upper_limit="2.03"/>
                    <measurement group_id="O2" value="0.611" lower_limit="0.197" upper_limit="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to Any AEI=Yes (n=67,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" lower_limit="0.427" upper_limit="2.22"/>
                    <measurement group_id="O2" value="0.647" lower_limit="0.201" upper_limit="1.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to Any AEI=No (n=1047,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.339" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.436" lower_limit="0.212" upper_limit="1.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to Any AE=Yes (n=77,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" lower_limit="0.464" upper_limit="2.10"/>
                    <measurement group_id="O2" value="0.647" lower_limit="0.204" upper_limit="1.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to Any AE=No (n=1037,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.337" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.408" lower_limit="0.209" upper_limit="1.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Due to Any Reason=Yes (n=106,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.416" upper_limit="2.06"/>
                    <measurement group_id="O2" value="0.600" lower_limit="0.197" upper_limit="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation Due to Any Reason=No (n=1008,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.332" upper_limit="2.02"/>
                    <measurement group_id="O2" value="0.626" lower_limit="0.626" upper_limit="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least 1 AEI=Yes (n=536,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.453" upper_limit="2.09"/>
                    <measurement group_id="O2" value="0.600" lower_limit="0.197" upper_limit="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least 1 AEI=No (578,1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.297" upper_limit="1.98"/>
                    <measurement group_id="O2" value="0.929" lower_limit="0.929" upper_limit="0.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least 1 AE=Yes (n=693,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" lower_limit="0.416" upper_limit="2.07"/>
                    <measurement group_id="O2" value="0.611" lower_limit="0.197" upper_limit="1.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Least 1 AE=No (n=421,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.294" upper_limit="1.97"/>
                    <measurement group_id="O2" value="NA">No participants in this category for this arm.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Simulated Percentage of Participants With Adverse Events of Interest</title>
        <description>The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates [weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. AEIs: 12 Weeks</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration. Number of participants analyzed is the number of participants simulated. Measured values are predicted values.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 250 μg OD</title>
            <description>Roflumilast 250 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg EOD</title>
            <description>Roflumilast 500 μg, orally, every other day (EOD) at least 1 dose in the Main Period</description>
          </group>
          <group group_id="O3">
            <title>Roflumilast 500 μg OD</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) at least 1 dose in the Main Period.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Simulated Percentage of Participants With Adverse Events of Interest</title>
          <description>The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates [weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.</description>
          <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration. Number of participants analyzed is the number of participants simulated. Measured values are predicted values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="1000"/>
                <count group_id="O3" value="1000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight=48 kg (tPDE4i=0.72,0.72,1.45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="0.352" upper_limit="2.03"/>
                    <measurement group_id="O2" value="53.2" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O3" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=74 kg (tPDE4i=0.65,0.65,1.30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="0.427" upper_limit="2.22"/>
                    <measurement group_id="O2" value="52.3" lower_limit="0.201" upper_limit="1.239"/>
                    <measurement group_id="O3" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=105 kg (tPDE4i=0.60.0.60,1.19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="0.339" upper_limit="2.02"/>
                    <measurement group_id="O2" value="51.7" lower_limit="0.212" upper_limit="1.069"/>
                    <measurement group_id="O3" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former Smoker (tPDE4i=0.65,0.65,1.30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="0.464" upper_limit="2.10"/>
                    <measurement group_id="O2" value="52.3" lower_limit="0.204" upper_limit="1.237"/>
                    <measurement group_id="O3" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker (tPDE4i=0.56,0.56,1.13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="0.337" upper_limit="2.02"/>
                    <measurement group_id="O2" value="42.5" lower_limit="0.209" upper_limit="1.006"/>
                    <measurement group_id="O3" value="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (tPDE4i=0.65,0.65,1.30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="0.416" upper_limit="2.06"/>
                    <measurement group_id="O2" value="52.3" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O3" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (tPDE4i=0.72,0.72,1.45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="0.332" upper_limit="2.02"/>
                    <measurement group_id="O2" value="53.2" lower_limit="0.626" upper_limit="0.626"/>
                    <measurement group_id="O3" value="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=51 (tPDE4i=0.58,0.58,1.15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" lower_limit="0.453" upper_limit="2.09"/>
                    <measurement group_id="O2" value="51.4" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O3" value="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=64 (tPDE4i=0.65,0.65,1.30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="0.297" upper_limit="1.98"/>
                    <measurement group_id="O2" value="52.3" lower_limit="0.929" upper_limit="0.929"/>
                    <measurement group_id="O3" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=77 (tPDE4i=0.72,0.72,1.44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="0.416" upper_limit="2.07"/>
                    <measurement group_id="O2" value="53.2" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O3" value="61.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With LAMA (tPDE4i=0.65,0.65,1.30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="0.294" upper_limit="1.97"/>
                    <measurement group_id="O2" value="52.3"/>
                    <measurement group_id="O3" value="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without LAMA (tPDE4i=0.65,0.65,1.30)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5"/>
                    <measurement group_id="O2" value="43.5"/>
                    <measurement group_id="O3" value="51.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12</title>
        <description>The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates [weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
        <time_frame>Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. FEV-1: Pre-dose and Weeks 4 and 12</time_frame>
        <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration. The number of participants analyzed is the number of participants simulated. Measured values are predicted values.</population>
        <group_list>
          <group group_id="O1">
            <title>Roflumilast 500 μg OD_CFB in FEV1 @ Week 4</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) for 12 weeks. Results for Change from Baseline in FEV1 at Week 4.</description>
          </group>
          <group group_id="O2">
            <title>Roflumilast 500 μg OD_CFB in FEV1 @ Week 12</title>
            <description>Roflumilast 500 μg, tablets, orally, once daily (OD) for 12 weeks. Results for Change from Baseline in FEV1 at Week 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12</title>
          <description>The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates [weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.</description>
          <population>Pharmacokinetic (PK) Set included all participants who had at least 1 quantifiable PK concentration. The number of participants analyzed is the number of participants simulated. Measured values are predicted values.</population>
          <units>milliliters (mL)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1000"/>
                <count group_id="O2" value="1000"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight=33.5 kg (tPDE4i=1.012,1.012)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=70 kg (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="0.201" upper_limit="1.239"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weight=160 kg (tPDE4i=0.681,0.681)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" lower_limit="0.212" upper_limit="1.069"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current Smoker (tPDE4i=0.729,0.729)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="0.204" upper_limit="1.237"/>
                    <measurement group_id="O2" value="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Former/Never Smoker (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="0.209" upper_limit="1.006"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (tPDE4i=0.937,0.937)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" lower_limit="0.626" upper_limit="0.626"/>
                    <measurement group_id="O2" value="49.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=40 years (tPDE4i=0.675,0.675)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O2" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=60 years (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5" lower_limit="0.929" upper_limit="0.929"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age=92 years (tPDE4i=1.06,1.06)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" lower_limit="0.197" upper_limit="1.243"/>
                    <measurement group_id="O2" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>non-Asian (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD_Not Very Severe (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD_Very Severe (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="39.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAMA=Yes (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAMA=No (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5"/>
                    <measurement group_id="O2" value="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%FEV1 Reversibility=-28% (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1"/>
                    <measurement group_id="O2" value="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%FEV1 Reversibility=10% (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%FEV1 Reversibility=147% (tPDE4i=0.839,0.839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Main Treatment Period: First dose of study drug to 30 days past last dose or first dose in the Down-Titration Period (Up to 114 Days). Down-Titration Period: First dose of study drug to 30 days past the last dose of study drug (Up to 86 Days).</time_frame>
      <desc>Due to the design of the study, the most common (≥ 2%) non-serious adverse events were determined separately for each period, the blinded Main Treatment Period and the open-label Down-Titration Period. A result of 0 means that the event did not meet the ≥ 2% threshold for that study period but did meet the threshold for the other study period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Roflumilast 250 μg OD Then 500 μg OD_Main Treatment Period</title>
          <description>Roflumilast 250 μg, tablets, orally, once daily (OD) for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="E2">
          <title>Roflumilast 500 μg EOD Then 500 μg OD_Main Treatment Period</title>
          <description>Roflumilast 500 μg, tablets, orally, every other day (EOD), and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="E3">
          <title>Roflumilast 500 μg OD_Main Treatment Period</title>
          <description>Roflumilast 500 μg tablets, orally, once daily for 12 weeks in the Main Treatment Period. Any participants not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="E4">
          <title>Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period</title>
          <description>Participants in the roflumilast 250 μg once daily (OD) then 500 μg OD who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="E5">
          <title>Roflumilast 500 μg EOD_Down-Titration Period</title>
          <description>Participants in the roflumilast 500 μg, every other day (EOD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
        <group group_id="E6">
          <title>Roflumilast 500 μg OD_Down Titration Period</title>
          <description>Participants in the roflumilast 500 μg once daily (OD) treatment arm who were not tolerating study treatment were prematurely discontinued and received roflumilast 250 μg, tablets, orally, once daily for 8 weeks in the open-label Down-Titration Period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <description>One treatment-emergent death occurred during treatment with roflumilast 500 μg OD and is not related (previous AE included severe syncope).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with roflumilast 250 μg OD then 500 μg OD and is not related (previous AE included moderate COPD).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <description>One treatment-emergent death occurred during treatment with roflumilast 250 μg OD then 500 μg OD and is not related (previous AE included moderate COPD).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Femoral hernia incarcerated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <description>One treatment-emergent death occurred during treatment with roflumilast 500 μg OD and is not related (previous AE included concurrent moderate haemoptysis).</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <description>One treatment-emergent death occurred during treatment with roflumilast 250 μg OD then 500 μg OD and is not related (previous AE included concurrent moderate pneumonia).</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <description>One treatment-emergent death occurred during treatment with roflumilast 500 µg EOD then 500 µg OD and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="272" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="113" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="129" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="115" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="115" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="441"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="437"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="443"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

